Tom Daulton Named CEO at Veranex

A changing of the guard is underway at Veranex.

The company has appointed industry veteran Tom Daulton as CEO, replacing David Dockhorn, who has assumed the newly created role of chief operating officer (COO). 

“I am proud of the company we are building and the impact we are making every day with our customers,” Dockhorn said. “Our global team has worked to build a company that uniquely addresses the whole suite of medtech customer needs—from medical device discovery to invention, manufacturing, preclinical, clinical/regulatory, market launch, and commercial—allowing our clients to work on a global scale. I am excited to strengthen our impact by focusing on building the operational teams that support organic growth as we continue to build out our capabilities and enhance our operations, while Tom focuses on leading the organization and helping it expand.”
 
Daulton brings more than 30 years of healthcare leadership experience to Veranex, joining from National Dentex Labs (NDX), where he served as chairman and CEO for the past seven years and built one of the largest dental lab networks in North America. His additional experience includes key roles at medical device and healthcare services organizations with global scale, including 20 years at Baxter, Allegiance Healthcare, and Cardinal Health. Daulton was also founder and CEO of Devicor Medical Products, which acquired Mammotome’s breast care business from Johnson & Johnson’s Ethicon Endo-Surgery. The addition of Daulton will further expand extensive device experience across the Veranex executive suite.
 
“I am thrilled to join this team and continue the progress David has already championed,” Daulton said. “As an end-to-end medtech service provider, Veranex is clearly poised for an exciting future. My background—including experience building two large global healthcare businesses—has afforded me a solid understanding of how to knit a variety of cultures together into a powerful, unified business. I look forward to working closely with the team to build on Veranex’s role as a leader in medtech innovation, providing solutions to our customers and continuing to raise the industry standard for both quality and speed to market.”
 
In his new role as COO, Dockhorn will focus on operational excellence as Veranex continues its global expansion through both acquisition-driven and organic growth. He will support Daulton in business integration and in building the organizational structure necessary to support Veranex’s growing global footprint. 
 
“The Veranex board is thrilled to welcome Tom to lead the company through this next stage of growth,” Veranex Board of Directors Chairman Patrick Donnelly said. “Tom is a proven leader with deep experience in medtech and in leading global companies. His experience, combined with David’s operational leadership expertise, enables Veranex to deepen our capability to help our clients deliver innovation that has a true impact on the lives of patients everywhere.”
 
Veranex is a global, tech-enabled service provider dedicated to the medtech industry. Offering expert guidance from concept to commercialization and across the development continuum, Veranex enables accelerated speed to market, controlled development costs, development risk mitigation, and accelerated market viability assessment. At every stage, Veranex customers realize efficiencies in cost and time, while its comprehensive solutions unify and streamline the entire development process. Veranex is backed by Summit Partners, Accelmed, and Lauxera Capital Partners.